Gliomas
Positron emission tomography (PET) is increasingly contributing to diagnosis and management decision in patients with brain tumours and especially gliomas. Through the use of FDG, amino acid tracers ([11C]-methionine, [18F]-fluoro-ethyl-tyrosine and [18F]
- PDF / 39,394,178 Bytes
- 1,270 Pages / 439.42 x 683.15 pts Page_size
- 37 Downloads / 169 Views
123
PET and SPECT in Neurology
Rudi A. J. O. Dierckx • Andreas Otte Erik F. J. de Vries • Aren van Waarde Editors
Klaus L. Leenders Guest Editor
PET and SPECT in Neurology Second Edition
Editors Rudi A. J. O. Dierckx Nuclear Medicine and Molecular Imaging University Medical Center Groningen Groningen The Netherlands Erik F. J. de Vries Nuclear Medicine and Molecular Imaging University Medical Center Groningen Groningen The Netherlands
Andreas Otte Faculty of Electrical Engineering, Medical Engineering and Computer Science Offenburg University Offenburg Germany Aren van Waarde Nuclear Medicine and Molecular Imaging University Medical Center Groningen Groningen The Netherlands
Guest Editor Klaus L. Leenders Neurology University Medical Center Groningen Groningen The Netherlands
ISBN 978-3-030-53167-6 ISBN 978-3-030-53168-3 (eBook) https://doi.org/10.1007/978-3-030-53168-3 © Springer Nature Switzerland AG 2021 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Foreword
When in 2014 the editors published the first edition of this 3-volume series, dedicated to the use of PET and SPECT in the CNS, a major undertaking saw the light in print. These were significant multi-authored books, providing the most comprehensive review of this challenging field at the time. Now, in 2020, a second edition is launched, demonstrating the success of this initial endeavour. With a further major effort, over 50% of the numerous chapters are either entirely novel or rewritten anew, by an impressive list of international contributors. The team deserves warm congratulations for this achievement. In 2014, PET-MR had just emerged as a novel imaging modality, and the medical applications of machine lear
